American Home Products and King Pharmaceuticals have entered into a co-promotion agreement to market King's ACE inhibitor Altace (ramipril) in the United States and Puerto Rico.
Altace, an ACE inhibitor currently indicated for hypertension and congestive heart failure, received worldwide attention after the Heart Outcomes Prevention Evaluation Study, involving more than 9,500 high-risk patients, found a combined 22 percent reduction in the relative risk of heart attack, stroke and cardiovascular death among patients taking ramipril.
In May, an FDA advisory committee unanimously recommended the approval of Altace for the additional and unique indications of significant reduction of cardiovascular death, myocardial infarction, stroke and "all-cause mortality" in patients at risk for cardiovascular events.
Altace will be jointly marketed by Wyeth-Ayerst, AHP's pharmaceutical division, and Bristol, Tenn.-based King. The product was launched in the United States by Hoechst in 1991 and acquired by King in 1998.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group